Intro

This chapter explores the Impulses 1 and 2 trials of Nintedanib, an antifibrotic drug for Idiopathic Pulmonary Fibrosis (IPF), and the prior treatment challenges faced by the medical community. The discussion highlights how these trials have significantly influenced the management of IPF and interstitial lung diseases, reshaping therapeutic approaches in light of earlier setbacks.